Recent advances in 1,3,4-thiadiazole-based anticancer agents: synthesis, molecular targets, docking studies, and structure-activity relationships.

Abstract

1,3,4-Thiadiazole compounds have potential as anticancer agents. In recent years, they have been found to be promising inhibitors of some of the major classes of cancer mediators, such as tyrosine kinases and phosphatases. The inhibition of VEGFR-2 and EGFR kinases is pivotal for blocking the signaling pathways and inhibiting tumor growth. The SHP2 protein, a key mediator of tumor growth, tends to combat cell proliferation under different types of carcinomic conditions. Thiadiazole core molecules are instrumental in inhibiting such mediators and act as antiproliferative agents. This review focuses on the recent trends in thiadiazole chemistry and the synthesis of thiadiazole-containing heterocyclic compounds, along with their anticancer activity. An in-depth analysis of molecular docking studies and structure-activity relationships (SARs) provides strong evidence for the design of new thiadiazole-based drug molecules. Recent advances in the field of thiadiazole-containing heterocyclic systems in terms of their anticancer activity have been discussed with exclusive coverage over the past five years, since 2021.

Abstract as supplied by the indexing source. © the authors / publisher.